These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 22385404)

  • 1. Targeting the epidermal growth factor receptor in solid tumor malignancies.
    Nedergaard MK; Hedegaard CJ; Poulsen HS
    BioDrugs; 2012 Apr; 26(2):83-99. PubMed ID: 22385404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor targeting in cancer: a review of trends and strategies.
    Yewale C; Baradia D; Vhora I; Patil S; Misra A
    Biomaterials; 2013 Nov; 34(34):8690-707. PubMed ID: 23953842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences.
    Dassonville O; Bozec A; Fischel JL; Milano G
    Crit Rev Oncol Hematol; 2007 Apr; 62(1):53-61. PubMed ID: 17324578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting of cells expressing wild-type EGFR and type-III mutant EGFR (EGFRvIII) by anti-EGFR MAb ICR62: a two-pronged attack for tumour therapy.
    Modjtahedi H; Moscatello DK; Box G; Green M; Shotton C; Lamb DJ; Reynolds LJ; Wong AJ; Dean C; Thomas H; Eccles S
    Int J Cancer; 2003 Jun; 105(2):273-80. PubMed ID: 12673691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single domain antibodies: a new concept for epidermal growth factor receptor and EGFRvIII targeting.
    Omidfar K; Shirvani Z
    DNA Cell Biol; 2012 Jun; 31(6):1015-26. PubMed ID: 22277093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.
    Baselga J; Arteaga CL
    J Clin Oncol; 2005 Apr; 23(11):2445-59. PubMed ID: 15753456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy.
    Blehm KN; Spiess PE; Bondaruk JE; Dujka ME; Villares GJ; Zhao YJ; Bogler O; Aldape KD; Grossman HB; Adam L; McConkey DJ; Czerniak BA; Dinney CP; Bar-Eli M
    Clin Cancer Res; 2006 Aug; 12(15):4671-7. PubMed ID: 16899617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidermal growth factor receptor: pathway, therapies, and pipeline.
    Goffin JR; Zbuk K
    Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal growth factor receptor targeting in cancer.
    Mendelsohn J; Baselga J
    Semin Oncol; 2006 Aug; 33(4):369-85. PubMed ID: 16890793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The ErbB/HER family of protein-tyrosine kinases and cancer.
    Roskoski R
    Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small-molecule EGFR tyrosine kinase inhibitors for the treatment of cancer.
    Lee CC; Shiao HY; Wang WC; Hsieh HP
    Expert Opin Investig Drugs; 2014 Oct; 23(10):1333-48. PubMed ID: 24921970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the epidermal growth factor receptor. Trials in head and neck and lung cancer.
    Saba NF; Khuri FR; Shin DM
    Oncology (Williston Park); 2006 Feb; 20(2):153-61; discussion 162, 166, 169 passim. PubMed ID: 16562649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa).
    Heimberger AB; Learn CA; Archer GE; McLendon RE; Chewning TA; Tuck FL; Pracyk JB; Friedman AH; Friedman HS; Bigner DD; Sampson JH
    Clin Cancer Res; 2002 Nov; 8(11):3496-502. PubMed ID: 12429640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential for molecularly targeted therapy against epidermal growth factor receptor ligands.
    Miyamoto S; Fukami T; Yagi H; Kuroki M; Yotsumoto F
    Anticancer Res; 2009 Mar; 29(3):823-30. PubMed ID: 19414315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rational bases for the development of EGFR inhibitors for cancer treatment.
    Bianco R; Gelardi T; Damiano V; Ciardiello F; Tortora G
    Int J Biochem Cell Biol; 2007; 39(7-8):1416-31. PubMed ID: 17596994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells.
    Mamot C; Drummond DC; Greiser U; Hong K; Kirpotin DB; Marks JD; Park JW
    Cancer Res; 2003 Jun; 63(12):3154-61. PubMed ID: 12810643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.
    Sok JC; Coppelli FM; Thomas SM; Lango MN; Xi S; Hunt JL; Freilino ML; Graner MW; Wikstrand CJ; Bigner DD; Gooding WE; Furnari FB; Grandis JR
    Clin Cancer Res; 2006 Sep; 12(17):5064-73. PubMed ID: 16951222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR-directed therapies to treat non-small-cell lung cancer.
    Ho C; Laskin J
    Expert Opin Investig Drugs; 2009 Aug; 18(8):1133-45. PubMed ID: 19572809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical development of HER3-targeting monoclonal antibodies: Perils and progress.
    Jacob W; James I; Hasmann M; Weisser M
    Cancer Treat Rev; 2018 Jul; 68():111-123. PubMed ID: 29944978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.